BioSpace News Archive

Regeneron Pharmaceuticals, Inc. and Sanofi announced the primary and all key secondary endpoints were met in a Phase 3 trial evaluating the investigational use of Dupixent® compared to placebo in adults currently on maximal standard-of-care inhaled therapy with uncontrolled chronic obstructive pulmonary disease and evidence of type 2 inflammation.

The Chemours Company, a global chemistry company with leading market positions in Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials, announces the appointment of Denise Dignam as President, Chemours Titanium Technologies and Chemical Solutions, effective April 1, 2023.

Tonix Pharmaceuticals Holding Corp. today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will deliver an oral presentation and the Company will present a poster at the 5th International Congress on Controversies in Fibromyalgia being held March 30-31, 2023 at the Austria Trend Hotel Savoyen Vienna, Vienna, Austria.

Biotechnology company Cambrium has launched its first product: NovaColl™. It is the first micro-molecular & 100% skin-identical collagen specifically designed for premium personal care formulations.

Monopar Therapeutics Inc. today announced fourth quarter and full-year 2022 financial results and summarized recent developments.

Alkermes plc (Nasdaq: ALKS) today announced the publication of results from its phase 3 ENLIGHTEN-Early study of LYBALVI ® (olanzapine and samidorphan) in the peer-reviewed publication, the Journal of Clinical Psychiatry.

GRIN Therapeutics Inc. today announced that the first patient has been dosed in the Honeycomb Study, the Company’s Phase 1B clinical trial of radiprodil.

Exscientia plc. Recent developments in the Company’s pipeline, collaborations, and operations as well as financial results for the fourth quarter and full year 2022 are summarised below.

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year ended Dec. 31, 2022 and provided a business update.

Bionik Laboratories Corp. today announced its InMotion® Robots will be on display at the Korea International Medical & Hospital Equipment Show (KIMES) from March 23 – March 26, 2023.